Table IV.

ZLnCopeptin in prediction of combined end point and its components in individuals with incident diabetes

	n total/n event	HR (95% CI)	P⁎
Primary end point (CAD + death + HF)†	460/102	1.48 (1.09-2.02)	.01
CAD‡	460/64	1.76 (1.17-2.65)	.007
HF§	460/20	1.43 (0.71-2.89)	.32
Death†	460/42	1.30 (0.82-2.08)	.27

HRs are expressed as per SD increment of ln-transformed copeptin.

^⁎Adjusted for age, sex, LDL, HDL, systolic BP, antihypertensive treatment, and smoking (model 1).

^†Model adjusted for prevalent CAD and prevalent HF on top of model 1 adjustment.

^‡Model adjusted for prevalent CAD on top of model 1 adjustment.

^§Model adjusted for prevalent HF on top of model 1 adjustment.